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https://doi.org/10.1016/j.cmet.2020.09.001SUMMARYLike normal hematopoietic stem cells, leukemic stem cells depend on their bonemarrow (BM)microenvironment
for survival, but the underlyingmechanisms remain largely unknown.We have studied the contribution of nestin+
BMmesenchymal stem cells (BMSCs) to MLL-AF9-driven acute myeloid leukemia (AML) development and che-
moresistance in vivo. Unlike bulk stroma, nestin+ BMSC numbers are not reduced in AML, but their function
changes tosupportAMLcells,at theexpenseofnon-mutatedhematopoieticstemcells (HSCs).Nestin+celldeple-
tiondelays leukemogenesis in primaryAMLmice andselectively decreasesAML, but not normal, cells in chimeric
mice. Nestin+BMSCs support survival andchemotherapy relapse of AML through increasedoxidative phosphor-
ylation, tricarboxylic acid (TCA) cycle activity, and glutathione (GSH)-mediated antioxidant defense. Therefore,
AML cells co-opt energy sources and antioxidant defense mechanisms from BMSCs to survive chemotherapy.CONTEXT AND SIGNIFICANCESeveral lines of evidence indicate that themicroenvironment plays a key role in leukemia development, chemo-
resistance, and, more recently, resistance to immunotherapy. Therefore, dissecting and targeting niche-driven
mechanisms of resistance might provide key adjuvant therapies to eradicate leukemia. This study shows that
BMSCs expressing the marker nestin directly support leukemia stem cell (LSC) survival and chemoresistance.
Nestin+ BMSCs increase energy production in LSCs through increased TCA cycle and oxidative phosphoryla-
tion (OXPHOS) and simultaneously provide LSCs with key antioxidant tools necessary to balance ROS levels
during leukemogenesis and chemotherapy. GSH-dependent antioxidant pathways emerge as key players in
the BMSC-LSC crosstalk and represent potential targets for adjuvant therapies in AML.INTRODUCTION
Acute myeloid leukemia (AML) is a cancer caused by accumula-
tion of poorly differentiated hematopoietic cells, which infiltrate
different tissues (Döhner et al., 2015). AML initiates through ge-Cell Metabolism 32, 829–843, Nove
This is an open access article undnetic or epigenetic lesions in hematopoietic stem cells (HSCs)
or myeloid progenitors that can transform into LSCs, which are
chemoresistant and cause tumor relapse (Bonnet and Dick,
1997; Huntly and Gilliland, 2005; Krivtsov and Armstrong,
2007; Krivtsov et al., 2006; Lapidot et al., 1994). Translocationsmber 3, 2020 ª 2020 The Author(s). Published by Elsevier Inc. 829
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESS Articlebetween the mixed lineage leukemia 1 gene (MLL1) and other
partner genes are a molecular hallmark of pediatric and often
therapy-related adult acute leukemia. Subsequently, they are
associated with frequent relapse and poor prognosis with cur-
rent therapies. One of the most common MLL translocations
generates the MLLT3-AF9 fusion gene (Krivtsov and Armstrong,
2007; Muntean and Hess, 2012; Tan et al., 2011). Murine models
of MLL-AF9 reproduce the human pathology (Corral et al., 1996;
Krivtsov et al., 2006; Milne, 2017) and generate a more aggres-
sive disease when the fusion oncogene is expressed in HSCs,
compared with more mature progenitors (George et al., 2016;
Krivtsov et al., 2013; Stavropoulou et al., 2016). Resembling
normal HSCs, LSCs rely on their local microenvironment for sur-
vival and chemoresistance (Méndez-Ferrer et al., 2020). Howev-
er, the underlying in vivo mechanisms remain incompletely
understood.
Although LSCs share some features with normal HSCs, their
metabolism is reprogrammed to meet high energy and
biomass production demands in AML (Baccelli et al., 2019;
Gallipoli et al., 2018). Although many cancer cells utilize aero-
bic glycolysis for energy production (Warburg et al., 1927),
cancer stem cells or chemoresistant cells in different tumors
(including AML) rely on mitochondrial oxidative phosphoryla-
tion (OXPHOS) for their high metabolic demand (Baccelli
et al., 2019; Farge et al., 2017; Jacque et al., 2015; Lagadinou
et al., 2013; Molina et al., 2018; Pollyea et al., 2018). However,
the cellular and molecular basis underlying the metabolic re-
programming of the LSC niche is largely unknown. Mitochon-
drial transfer from BM mesenchymal stem cells (BMSCs) to
AML cells in vitro has been recently described as a mecha-
nism that provides AML cells with additional energy. This
transfer increases upon chemotherapy and was proposed as
an additional mechanism of resistance by reducing mitochon-
drial depolarization (Marlein et al., 2017; Moschoi et al., 2016).
However, AML cells have abnormally high reactive oxygen
species (ROS) levels (Li et al., 2011), and it remains unclear
how AML cells are able to cope with the additional ROS re-
sulting from increased mitochondrial content. Indeed, cellular
proliferation and survival depend on critically fine-tuned levels
of ROS, which are mainly generated by the mitochondria. AML
cells are able to maintain relatively high ROS levels without
reaching a cytotoxic level through increased activity of antiox-
idant pathways (Li et al., 2011). However, the possible role of
the microenvironment in balancing ROS levels and providing
AML cells with antioxidant defense in vivo remains largely
unexplored.
BMSCs expressing the intermediate filament protein nestin
provide HSC niche function (Méndez-Ferrer et al., 2010) and
largely overlap with BMSCs labeled in subsequent studies us-
ing alternative markers (Ding et al., 2012; Greenbaum et al.,
2013; Mende et al., 2019; Méndez-Ferrer, 2019; Omatsu
et al., 2010; Park et al., 2012). Nestin+ niches are reduced in hu-
mans or mice with chronic myeloproliferative neoplasms (Ar-
ranz et al., 2014), which can be considered preleukemic disor-
ders due to their higher incidence of leukemic transformation.
In contrast, increased number of BM nestin+ cells have been
reported in AML mice transplanted with serially passaged he-
matopoietic cells transformed with a retrovirally expressed
MLL-AF9 fusion oncogene (Hanoun et al., 2014). However,830 Cell Metabolism 32, 829–843, November 3, 2020whether and how nestin+ cells play a role during leukemogen-
esis remain unknown.
Here, we have studied the contribution of nestin+ cells to
MLL-AF9-driven AML development and resistance to conven-
tional chemotherapy in vivo. The results demonstrate that
nestin+ cells contribute to AML progression by increasing the
bioenergetic capacity of AML cells and facilitating their chemo-
resistance. BMSC-dependent increased OXPHOS, tricarbox-
ylic acid (TCA) cycle and glutathione (GSH)-mediated antioxi-
dant defense against excessive ROS allow AML cells to meet
their high metabolic demands and survive chemotherapy. Tar-
geting these BMSC-dependent AML survival pathways can
synergize with conventional chemotherapy to eliminate chemo-
resistant cells.
RESULTS
Unlike Bulk Stromal Cells, Nestin+ Niche Cells Are
Preserved in AML
Nestin+ BMSCs are HSC niche-forming cells (Méndez-Ferrer
et al., 2010), which have been reported to undergo diametri-
cally opposite numerical changes in different myeloprolifera-
tive disorders (Arranz et al., 2014; Hanoun et al., 2014). To
investigate whether nestin+ BM cells are affected in human
AML, we performed immunohistochemistry for the human
NESTIN protein in BM biopsies from MLL-AF9+ (n = 5) or
MLL-AF9 (n = 56) AML patients and control donors (n = 12)
(Figures 1A–1C). BM NESTIN+ niches increased 4–5-fold in
AML patients regardless of the presence of the MLL-AF9
translocation (Figures 1D and 1E). These results are consis-
tent with findings in a retrovirally induced MLL-AF9 AML
mouse model (Hanoun et al., 2014) and contrast with reduced
NESTIN+ niches in human or mouse MPN (Arranz et al., 2014;
Drexler et al., 2019).
To reproduce these findings in an inducible AML mouse
model, we have used the doxycycline-inducible rtTA;MLL-AF9
(referred as iMLL-AF9) mouse strain (Stavropoulou et al.,
2016). Both primary AML mice following induction and irradi-
ated C57BL/6 recipient mice transplanted with iMLL-AF9 BM
cells develop myelo-monoblastic AML that closely mimics the
human disease (Stavropoulou et al., 2016). To visualize nestin+
cells, iMLL-AF9 mice were intercrossed with Nestin-GFP re-
porter mice, which express the green fluorescent protein
(GFP) under the regulatory elements of the nestin (Nes) pro-
moter (Méndez-Ferrer et al., 2010; Mignone et al., 2004). AML
was induced in vivo with doxycycline (Figure 1F). Nestin-
GFPhigh cells are associated with central arterioles and also
with transition zone vessels that connect arterioles with sinu-
soids near the bone (Garcı́a-Garcı́a et al., 2019; Itkin et al.,
2016; Kunisaki et al., 2013; Kusumbe et al., 2014). Nestin-
GFPlow cells coincide with LepR+ cells in central BM sinusoids
(Ding et al., 2012). Nes-GFP;iMLL-AF9 mice sacrificed 8–
10 weeks after AML induction showed a significant reduction
in the number of BM CD45Ter119CD31 stromal cells,
compared with disease-free controls (Figure 1G). However,
we observed highly variable but overall unchanged numbers
of Nestin-GFPhigh/low BMSCs. The observation of selective
retention of nestin+ cells raised our interest to study whether
these cells might play an active role in leukemogenesis.
Figure 1. Unlike Bulk BM Stromal Cells,
Nestin+ Niche Cells Are Preserved in Human
andMurine AML and Promote Leukemogen-
esis
(A–D) Representative examples of immunohisto-
chemistry for human NESTIN (brown) and human
CD34 (pink) in BM samples from AML patients.
CD34 AML (A), CD34+ AML ([B] and [C]), and
MLL-AF9+ AML (D) show increased NESTIN+
niches (arrows) and CD34+ vessels (arrowheads).
Scale bar, 10 mm (A–C), 100 mm (D).
(E) Quantification of NESTIN+ niches from (A and
B) (control n = 12; MLL-AF9 AML n = 56; MLL-
AF9+ AML n = 5). *p < 0.05, **p < 0.01, one-way
ANOVA and Bonferroni comparisons.
(F) Scheme showing the induction of AML in pri-
mary, non-transplanted Nes-GFP mice to study
BMSC changes during leukemogenesis.
(G) Fold change in the number of BM stromal cells
(CD45 Ter119CD31) and BMSCs expressing
low or high levels of Nes-GFP (NesGFPlow/high) in
the BM of control (C) Nes-GFP;rtTAmice and Nes-
GFP;rtTA;iMLL-AF9 (AML) mice. Numbers were
normalized with the average ofWT controls in each
independent experiment. Mice were analyzed
8–10 weeks after inducing MLL-AF9 expression.
Dots represent data from individual mice (n = 2
independent experiments). Data are mean ± SEM.
Unpaired two-tailed t test.
(H) Scheme showing experimental depletion
of nestin+ cells in primary, non-transplanted
leukemic mice. MLL-AF9 expression (iMLL-AF9) is
induced with doxycycline.
(I) Nestin+ cell depletion extends AML mouse
survival. Kaplan-Meier survival curve of primary
iMLL-AF9 mice in control group (black, n = 9) or
after nestin+ cell depletion (red, n = 11). Log-
rank test.
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The persistence of nestin+ cells in highly infiltrated BM of AML
patients and mice suggested that these cells may actively
contribute to disease progression, possibly by providing support
to leukemic blasts, as previously suggested for other stromal
cells, albeit through in vitro rather than in vivo studies (Brenner
et al., 2017; Corradi et al., 2018; Geyh et al., 2016; Kornblau
et al., 2018; Wu et al., 2018; Yehudai-Resheff et al., 2019). To
assess the role of nestin+ cells in vivo, we took advantage of a
mouse model that allows conditional depletion of nestin+ cells.
We intercrossed mice carrying tamoxifen-inducible CreERT2 re-
combinase under the control of Nes regulatory elements (Nes-
CreERT2) (Balordi and Fishell, 2007) with the R26lacZbpAflowDTA
strain (Brockschnieder et al., 2006), which harbors a Cre-induc-Cell Metabible diphtheria toxin A allele allowing for
conditional depletion of nestin+ cells
upon tamoxifen treatment (Figure S1A).
As early as 25 days after tamoxifen appli-
cation, Nes-creERT2;R26lacZbpAfloxDTA
mice (abbreviated as Nes-creERT2;iDTA)
showed decreased numbers of BMSCs
measured functionally (by colony-forming
unit fibroblasts, CFU-F) or immunopheno-typically (CD90+), whereas CD31+ BMendothelial cells appeared
unaffected (Figures S1B–S1D). Conditional depletion of nestin+
BM cells in healthy mice was associated with 2-fold decreased
HSC activity, measured by long-term competitive repopulation
assays (Figure S1E). These results confirm the HSC niche
dependence on nestin+ BMSCs (Méndez-Ferrer et al., 2010)
and validate the nestin+ cell depletion model.
To test the role of nestin+ cells in AML, Nes-creERT2;iDTA mice
were intercrossed with iMLL-AF9 mice. Compound iMLL-AF9;
Nes-creERT2;iDTAmice and their control littermates were adminis-
tered doxycycline to induceAML and tamoxifen to deplete nestin+
cells (Figure1H).Notably, the eliminationofnestin+ cells uponAML
development significantly extended mouse survival (Figure 1I),
suggesting that nestin+ cells promote leukemogenesis in vivo.olism 32, 829–843, November 3, 2020 831
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Leukemogenesis
The results thus far suggested that BM nestin+ cells not only sup-
port normal HSCs in wild type (WT) (healthy) mice (Méndez-Ferrer
et al., 2010) (Figure S1E) but also support leukemogenesis inmice
(Figure 1H). To directly compare the role of nestin+ cells in normal
hematopoiesis and leukemia development,Nes-creERT2;iDTA and
their littermate iDTA controls were competitively transplantedwith
WTBMcells and non-induced iMLL-AF9BMcells, allowing simul-
taneousmonitoring of normal and leukemic hematopoiesis, which
were distinguished in the same animal by the expression of
different CD45 surface marker isoforms (Figure 2A). We observed
that depletion of nestin+ cells during the course of AML develop-
ment selectively diminished the number of MLL-AF9+ cells in pe-
ripheral blood, spleen, and BM and reduced the number of
leukemic hematopoietic-lineage-negative (lin) progenitor cells,
without affecting normal hematopoiesis (Figures 2B–2D). Among
immature hematopoietic cells, linckitlowsca1 cells (LKlo) cells
preferentially expanded by the MLL-AF9 oncogene and tended
to decrease upon nestin+ cell depletion (Figures 2E, S1F, and
S1G). This result suggests that AML cells instruct nestin+ cells
to promote leukemogenesis at the expense of their role support-
ing normal HSCs.
Nestin+ Cells Support In Vivo Chemoresistance in AML
Since nestin+ cells support AML cells, we next tested their po-
tential to maintain resistant cells and help them evade AML
chemotherapy. For that purpose, nestin+ cell depletion was
combined with cytarabine (AraC—a chemotherapeutic drug
frequently used in AML therapy) (Burnett et al., 2011; Tamamyan
et al., 2017) in mice transplanted simultaneously with WT and
iMLL-AF9 cells (Figure S1H). Independently of nestin+ cell deple-
tion, AraC significantly reduced the peripheral white blood cell
(WBC) counts. However, compared with control mice, AML
relapse was significantly delayed in Nes-creERT2;iDTAmice (Fig-
ure 2F). As a result, splenomegaly was only detected at the time
of analysis in symptomatic control mice treated with chemo-
therapy only, but not in those with nestin+ cell depletion (Fig-
ure 2G). Consistent with the previous results, the combination
of AraCwith nestin+ cell depletion significantly reduced leukemic
cells but did not affect non-leukemic BM hematopoietic cells
(compare Figures 2D and 2H). Combined AraC and nestin+ cell
depletion preferentially decreased LKlo cells (Figure 2I), whereas
it did not alter leukemic/non-leukemic LSK/LK cells (Figures S1I
and S1J). Altogether, these results suggest that AML cells high-
jack HSC niche functions of nestin+ cells to evade
chemotherapy.
BMSCs Support Leukemic Blast Survival and
Chemoresistance In Vitro
To investigate the mechanisms by which nestin+ cells support
AML development and chemoresistance, we optimized an
in vitro system to grow human or murine NESTIN+ BMSCs as
mesenspheres, which exhibit increased in vivo self-renewal
and support of HSCs, compared with standard plastic-adherent
BMSCs (Ghazanfari et al., 2016; Isern et al., 2013; Méndez-Fer-
rer et al., 2010). Upon coculturing mesenspheres with AML
blasts (Figure 3A), more leukemic blasts survived AraC treatment
(Figure 3B). Importantly, human mesenspheres provided832 Cell Metabolism 32, 829–843, November 3, 2020enhanced chemoprotection of human AML blasts, compared
with plastic-adherent BMSCs from the same donors (Figure 3C).
Chemoprotection was similarly detected upon coculturing hu-
man mesenspheres with human BM CD45+ blasts or human
CD34+ HSC-enriched cells (Figures 3D and 3E). These data sug-
gest that nestin+ BMSCs support survival and chemotherapy
escape of mouse and human AML cells in vitro.
BMSCs Enhance Leukemic Blast Bioenergetics by
Increasing OXPHOS and TCA Cycle
Cumulative evidence suggest that the BM microenvironment
provides critical metabolic support to AML cells (Méndez-Ferrer
et al., 2020). Therefore, metabolic studies were conducted to
investigate the mechanisms explaining increased AML survival
in coculture with BMSCs. Although most cancer cells fulfill their
metabolic requirements by aerobic glycolysis (Warburg et al.,
1927), cancer stem cells or chemoresistant cells in different tu-
mors, including AML, seem to rely on mitochondrial OXPHOS
(Baccelli et al., 2019; Farge et al., 2017; Jacque et al., 2015; Mo-
lina et al., 2018; Pollyea et al., 2018). To investigate the possible
metabolic dependency of leukemic blasts from BMSCs, we
measured the oxygen consumption rate (OCR)—a readout of
mitochondrial function—in leukemic cells previously cultured
for 24 h alone or in coculture with BMmesenspheres in presence
of AraC. OCR significantly increased in leukemic blasts, which
had been previously cocultured with BM mesenspheres,
compared with blasts cultured alone (Figure 3F). The basal and
maximal respiratory rate of AraC-treated leukemic blasts
increased >5-fold in the presence of BMSCs (Figures 3G and
3H). The spare respiratory capacity, which reflects the difference
between the maximal and the basal respiratory rate, increased
10-fold in coculture (Figure 3I). Consequently, ATP production
was doubled in coculture, compared with monoculture (Fig-
ure 3J). Together, these results suggest that BMSCs promote
AML cell survival under chemotherapy by increasing their bioen-
ergetic capacity.
To further characterize the metabolic profile of chemotherapy-
treated leukemic blasts, we analyzed the intracellular metabolite
levels by liquid chromatography-mass spectrometry (LC-MS). In
coculture with mesenspheres, leukemic blasts exhibited 2–3-
fold higher levels of the TCA cycle intermediates fumarate, a-ke-
toglutarate (a-KG), and malate (Figure 3K), suggesting that
BMSCs stimulate TCA cycle in AML cells. Since TCA cycle takes
place in the mitochondria, we labeled the mitochondria of
BMSCs and AML cells using different fluorochromes. After
AraC treatment in coculture, the transfer of mitochondria from
BMSCs to leukemic blasts was observed as a potential source
of increased energy (Figures 3L and 3M), confirming and extend-
ing previous observations with plastic-adherent cells (Marlein
et al., 2017; Moschoi et al., 2016).
BMSCs Increase Antioxidant Defenses in Leukemic
Blasts Facilitating Chemoresistance
The mitochondrial transfer from BMSCs to AML cells raised the
question of its possible impact on cellular ROS. Indeed, AML
cells already exhibit abnormally high mitochondrial-derived
ROS at baseline (Li et al., 2011), and it is unclear how AML cells
can survive putatively additional ROS derived from BMSC-
derived mitochondria (Figures 3L and 3M). To address this
Figure 2. Nestin+ Cells Promote Leukemia Chemoresistance In Vivo
(A) Scheme showing the experimental setting to simultaneously study the impact of nestin+ cell depletion on healthy and leukemic hematopoietic cells. Lethally
irradiated CD45.2 control mice or Nes-creERT2;iDTA mice were transplanted with 106 iAML (rtTA;MLL-AF9) CD45.2+ BM nucleated cells and 106 CD45.1+ WT
BM nucleated cells. Doxycycline administration started 2 weeks after transplant; tamoxifen was administered 4 weeks post-transplant and mice were sacrificed
and analyzed 4 weeks later.
(B–D) Number of WT and MLL-AF9+ WBC (B), spleen weight (C), BM nucleated, and lineage-negative cells (D).
(E) BM linckitlosca1 (LKlo) cells. Data in (D and E) represent the cellularity of 4 limbs, sternum, and spine (n = 18 mice/group, pooled from 3 independent
experiments).
(F–I) Nestin+ cells support chemoresistance in AML mice. (F) WBCs, (G) spleen weight, (H) BM nucleated cells, and (I) LKlo cells in control (iDTA)
or Nes-creERT2;iDTA (iDTA+) mice transplanted with a mixture of WT and iMLL-AF9 BM cells, receiving tamoxifen and AraC treatment simulta-
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Figure 3. BMSCs Support Leukemic Blast
Survival, Chemoresistance, and Bioener-
getics
(A) Scheme showing the different culture condi-
tions and cells tested.
(B) Frequency of alive (AnnexinVDAPI) cells
24 h after AraC treatment (n = 19).
(C) Frequency of alive human AML cells mono-
cultured (M) or cocultured or cocultured (C) with
human mesenspheres or adherent BMSCs for 24 h
under AraC treatment (n = 3–5). *p < 0.05; One-way
ANOVA and Bonferroni comparisons.
(D and E) Frequency of alive CD45+ (D, n = 8) cells
or CD34+ HSPCs (E, n = 3) from human AML BM
24 h after AraC in monoculture (black) or coculture
(red) with BMSCs expanded as mesenspheres
from AML patients (n = 8). *p < 0.05; **p < 0.01;
paired two-tailed t test.
(F) OCR indicating mitochondrial respiration after
oligomycin, FCCP and antimycin A/rotenone
treatment in leukemic blasts cultured alone or
previously cocultured with mesenspheres for 24 h
in presence of AraC.
(G–J) Seahorse measurement of basal respiration
(G), maximal respiration (H), spare respiratory ca-
pacity (I), and ATP content (J) in murine leukemic
blasts monocultured (black columns) or cocultured
with BMSCs (red columns); n = 6 independent
experiments. Data represent mean ± SEM. *p <
0.05; **p < 0.01; ***p < 0.001; unpaired two-tailed t
test.
(K) Levels of the TCA cycle metabolites fumarate,
ɑ-KG, and malate measured by LC-MS in murine
leukemic blasts monocultured (black columns) or
cocultured with BMSCs (red columns); n = 5 in-
dependent experiments with 4 biological repli-
cates each.
(L) Frequency of AML blasts uptaking MitoTracker
Red+ mitochondria previously stained in BMSCs
only, before the coculture with AML cells under
AraC treatment; n = 4 independent experiments;
*p < 0.05; paired two-tailed t test.
(M) Representative flow cytometry diagrams
showing CD45 (green) and MitoTracker Red (red)
fluorescence in murine AML blasts monocultured
or cocultured with BMSCs, which were previously
stained with MitoTracker Red to label their mito-
chondria. The frequencies of gated cell pop-
ulations are indicated. The red box highlights the
increased frequency of BMSC-derived mitochon-
dria in AML cells after AraC treatment.
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DHR123. As expected (Amarante-Mendes et al., 1998), AraC
treatment significantly increased ROS levels in the leukemic
blasts (Figure S2A). Interestingly, despite mitochondrial uptake
and increased OXPHOS, AML cells cocultured with BMSCs
showed decreased ROS levels (Figure 4A). Excessive ROS levels
can cause cell damage and death by inducing lipid peroxidation
(Barrera, 2012). Like ROS, lipid peroxidation similarly decreased
in leukemic blasts cocultured with mesenspheres (Figure 4B),
indicating that BMSCs protect AML cells from chemotherapy-
derived ROS-induced cell damage. These effects required cell
contact between BMSCs and AML cells since they were not re-
produced in transwell coculture or using conditioned medium
(Figures S2B–S2E).834 Cell Metabolism 32, 829–843, November 3, 2020The Glutathione System Mediates Antioxidant
Protection from Chemotherapy by BMSCs
To investigate potential microenvironmental pathways
increasing the ability of AML cells to buffer ROS, we performed
RNA-seq in CD45CD31Ter119Nes-GFP+ BMSCs isolated
from control WTmice or primary AMLmice upon leukemia devel-
opment. Whereas ~900 genes were upregulated, ~600 genes
appeared downregulated in nestin+ BMSCs from AML mice (Ta-
ble S1). GO enrichment analysis of significantly upregulated
genes in AMLmice showed 54 genes belonging to themitochon-
drion and highlighted mitochondrial-associated pathways, such
as mitochondrial translation, mitochondrion organization, and
mitochondrial respiratory chain complex assembly and biogen-
esis (Figure 4C; complete analysis is shown in Table S1).
Figure 4. BMSCs Provide Leukemic Blasts
with Antioxidant Defense during Chemo-
therapy
(A and B) ROS measured by DH123 staining
(A) and lipid peroxidation detected with
BODIPY581/591 (B) in AML blasts and BMSCs
cultured alone or together for 24 h in presence
of AraC. Each dot is a biological replicate. **p <
0.05; unpaired two-tailed t test.
(C) Selected pathways from the GO enrichment
analysis of significantly upregulated mRNA (RNA-
seq) of CD45CD31Ter119Nes-GFP+ cells
isolated from the BM of primary iMLL-AF9 mice or
control mice. The GO term, adjusted p value and
differentially expressed genes in each category are
indicated.
(D) Selected pathways from the GSEA analysis of
RNA-seq of hematopoietic-lineage-negative cki-
tlow (LKlo) cells isolated from the BM of AML mice
with or without nestin+ cell depletion. Lethally
irradiated CD45.2 control mice or Nes-creER-
T2;iDTA mice were transplanted with 106 iAML
(rtTA;MLL-AF9) CD45.2+ BM nucleated cells and
106 CD45.1+ WT BM nucleated cells. Doxycycline
administration started 2 weeks after transplant;
tamoxifen was administered 4 weeks post-trans-
plant; and mice were sacrificed and analyzed
4 weeks later. BM MLL-AF9+ lin ckitlow (LKlo)
cells were sorted from leukemic mice with or
without nestin+ cell depletion. The pathway term,
signature, and adjusted p value are indicated.
(E) Heatmap showing antioxidant and GSH related
among the top upregulated (red) protein pathways
detected by proteomics in AraC-treated AML
blasts cultured alone or cocultured with mesen-
spheres for 24 h. Quantitative proteomics results
were analyzed using the WSPP statistical model
(Navarro et al., 2014) and expressed in log2 fold
change values in units of SD (Zq) with respect to
baseline. Significant protein changes (adjusted p <
0.05) are indicated; two-sided Fisher test, 3 bio-
logical replicates in each condition.
(F) SBT analysis (Garcı́a-Marqués et al., 2016) to
detect changes in functional categories due to
coordinated protein behavior. The analysis de-
tected significantly increased pathways (positive
values of Zq indicate increased protein changes)
compared with the theoretical N(0,1) distribution (black curve); for comparison, the distribution of Zq values of all the proteome is also shown (red curve). The
panel displays the cumulative distributions of Zq from proteins belonging to a set of representative altered categories, showing the high coordination of protein
responses in these pathways.
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were increased, including selenocysteine regulation of methio-
nine biosynthesis, which is essential for the generation of the
cellular antioxidant GSH. To investigate the corresponding tran-
script alterations in the AML cells regulated by nestin+ BMSCs,
we performed RNA-seq in BM LKlo cells obtained from AML
mice with/without nestin+ cell depletion. Consistent with the
transcriptomics changes observed in BMSCs, gene set enrich-
ment analysis (GSEA) showed significantly increased mitochon-
drial pathways, such as OXPHOS and TCA cycle, in AML LKlo
cells following nestin+ cell depletion (Figures 4D and S2F; Table
S2).
To further investigate the functional consequences of these
transcriptomics alterations in nestin+ BMSCs and, particularly,when leukemic cells are challenged by chemotherapy, we per-
formed proteomic analysis of AraC-treated AMLblastsmonocul-
tured or cocultured with mesenspheres for 24 h. These analyses
revealed differential abundance of proteins (Table S3), including
11 antioxidant proteins associated with detoxification and/or
GSH metabolism, which were significantly upregulated in cocul-
ture (Figure 4E). The quantified proteins were grouped into onto-
logical categories from GO, KEGG, or REACTOME databases,
and the systems biology triangle (SBT) model (Garcı́a-Marqués
et al., 2016) was used to analyze coordinated increase or
decrease of proteins belonging to these categories. The analysis
revealed statistically significant coordinated increases in the
proteins belonging to glucose metabolism, pentose phosphate
pathway (PPP), GSH metabolism and detoxification, includingCell Metabolism 32, 829–843, November 3, 2020 835
Figure 5. BMSC-Dependent GSH-Related Pathways Protect AML Cells from Chemotherapy
(A) Reduced glutathione (GSH) measured by mBCI staining in AML blasts and BMSCs cultured alone or together for 24 h in presence of AraC.
(B) Frequency of AraC-treated GSHlo/hi AML cells monocultured (upper bar) or cocultured with BMSCs (middle and lower bar), separating leukemic blasts, which
contain mitochondria derived from previously labeled BMSCs (lower bar) from those containing only blasts’ mitochondria (middle and upper bars); n = 4–5.
(C) mRNA expression of Gpx1 and Gpx3 in AML blasts and BMSCs cultured alone or together for 24 h in presence of AraC.
(D) GSHmeasured bymBCI staining in LKloWT or iMLL-AF9 cells frommice with/without nestin+ cell depletion (Nes-creERT2;iDTA and control littermates) treated
as in Figure S3H. Mice were treated with standard chemotherapy (AraC+) or vehicle (AraC). (A, C, and D) Each dot represents a biological replicate. Data
represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. Unpaired two-tailed t test. (B and D) One-way ANOVA followed by pairwise Bonferroni comparisons.
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GSH to GSSG for detoxification (Figure 4F). Therefore, we
measured reduced GSH in AraC-treated leukemic blasts and
found it significantly increased in coculture with mesenspheres,
compared with monoculture (Figure 5A). To correlate GSH levels
with mitochondrial transfer, the mitochondria of BMSCs and
leukemic blasts were stained with different colors before cocul-
ture. Remarkably, GSH levels were highest in those leukemic
blasts that had uptaken mitochondria from BMSCs (Figure 5B).
Increased GSH also correlated with augmented mRNA expres-
sion of key detoxifying enzymes that utilize GSH as a substrate.
Notably, mRNA expression of Gpx1 and Gpx3 increased in the
cocultured leukemic blasts (Figure 5C), confirming the proteomic
results, whereas this was not the case for other relevant detoxi-
fying enzymes (Figures S3A–S3G). These results suggest that
BMSCs specifically protect leukemic cells from chemotherapy-
induced ROS by increasing GSH availability and utilization,
mainly via the Gpx system.
To address in vivo the relevance of the GSH-dependent
protection of AML cells from excessive ROS associated with836 Cell Metabolism 32, 829–843, November 3, 2020chemotherapy by BMSCs, Nes-creERT2;iDTA mice and their
littermate controls were competitively transplanted with
normal and iMLL-AF9 BM cells. Doxycycline was adminis-
tered after 2 weeks to induce AML, and nestin+ cells were
depleted by tamoxifen administration upon leukemia develop-
ment, i.e., once peripheric blood showed high WBC (see
STAR Methods), around 5 weeks later (Figure S3H). Mice
were acutely injected after 24 h with a single dose of AraC
and 24 h later BM LKlo cells were analyzed, as this cell popu-
lation preferentially expanded in the leukemic mice depen-
dently on nestin+ cells (Figure 2E). GSH levels were signifi-
cantly higher in leukemic LKlo cells than in WT LKlo cells.
Moreover, GSH levels increased in leukemic LKlo (but not in
WT cells) 24 h after AraC application. Despite the limitations
and inherent variability of this in vivo approach, nestin+ cell
depletion overall impaired the capacity of AML LKlo cells to
boost GSH levels after chemotherapy (Figure 5D). Collectively,
these results suggest that AML cells rely on BMSCs to in-
crease their GSH-dependent antioxidant defense to escape
chemotherapy.
Figure 6. BMSCs Protect Leukemic Blasts
from Chemotherapy through GSH Recycling
and Oxidation by Gpx
(A and B) mRNA expression of the genes encoding
(A) the catalytic subunit of gamma-gluta-
mylcysteine synthetase (Gclc), which is the first
rate-limiting enzyme of GSH synthesis, and (B)
GSH reductase (Gsr), required for GSH recycling in
AML blasts and BMSCs, cultured alone (black,
blasts; gray, BMSCs) or together (red, blasts;
green, BMSCs) for 24 h in presence of AraC. Each
dot is a biological replicate.
(C) NADPH/NADP+ ratio in sorted CD45+ leukemic
blasts after monoculture (black) or coculture
with BMSCs (red), in the presence/absence of
AraC (n = 3).
(D) Schematic representation of the TCA cycle and
glutathione redox cycle, indicating with arrows
upregulated (red) and downregulated (black) mol-
ecules in coculture.
(E) Frequency of alive (AnnexinVDAPI) AML
cells 24 h after treatment of monoculture (black) or
cocultured (red) cells with vehicle (ctrl), AraC, the
Gpx inhibitor mercaptosuccinic acid (MSA,
1.6 mM) or both drugs (n = 6).
(B–E) Data represent mean ± SEM. *p < 0.05; **p <
0.01; ***p < 0.001. (B and C) Unpaired 2-tailed t
test. (D–F) One-way ANOVA followed by pairwise
Bonferroni comparisons.
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AML Cells
To further study how BMSCs influence the usage of GSH by
AML cells, we measured the expression of enzymes required
for GSH synthesis and recycling in AML blasts. Intriguingly,
mRNA expression of the catalytic subunit of gamma-glutamyl-
cysteine synthetase (Gclc), which is the first rate-limiting
enzyme of GSH synthesis, was reduced in AraC-treated AML
blasts cocultured with BMSCs (Figure 6A), arguing against de
novo GSH synthesis stimulated by BMSCs. However, GSH re-
cycling following transcriptional upregulation of GSH reductase
(encoded by Gsr) is reportedly critical for protection against
ROS-induced cell death (Harvey et al., 2009). Indeed, we
observed increased Gsr mRNA expression in AraC-treated
AML cells cocultured with BMSCs (Figure 6B), validating the
proteomic data (Figure 4E). Gsr requires NADPH to reduce
oxidized glutathione (GSSG) and generate GSH. Supporting
BMSC-mediated GSH recycling, the ratio of NADPH/NADP+
doubled in coculture (Figure 6C). Altogether, these metabolic
studies suggest that BMSCs stimulate the TCA cycle and
GSH recycling in leukemic blasts.Cell MetabTargeting BMSCs-Induced
Antioxidant Defense Improves
Antileukemic Chemotherapy
In Vitro and In Vivo
Since the metabolomic, proteomic, and
transcriptomic analyses suggested the
possible relevance of Gpx1 in BMSC-
dependent AML protection from chemo-
therapy, the Gpx1 inhibitor mercaptosuc-
cinic acid (MSA) was tested in culture.MSA was not toxic for BMSCs at the concentration used to treat
leukemic blasts (Figure S4A) and was sufficient to abrogate the
chemoprotection of AML cells by the mesenspheres (Figures
6D and 6E).
To test whether targeting GSH activity in AML could be thera-
peutic in vivo, the effect of GSH was studied in combination with
standard chemotherapy in mice. Due to in vivo toxicity of MSA
(Dhall et al., 2014), buthionine sulfoximine (BSO), which is a
potent inhibitor of g-glutamylcysteine synthetase (g-GCS), was
used to inhibit GSH biosynthesis in vivo (Tagde et al., 2014).
Lethally irradiated mice were competitively transplanted with
WT and non-induced iMLL-AF9 BM cells, and doxycycline was
administered to induce AML. Mice were treated with chemo-
therapy 5 weeks after transplantation following a regimen
mimicking clinical AML induction therapy. This treatment con-
sisted of ‘‘5 + 3’’ i.p. injections of cytarabine (100 mg/kg/day
over 5 days) and doxorubicin (3 mg/kg/day over 3 days) (Zuber
et al., 2009). Mice were additionally treated with BSO (400 mg/
kg/day for 10 days during and immediately after standard
chemotherapy) or vehicle (Figure 7A). Notably, the combination
therapy reduced 5-fold leukemic LSK cells and 2-fold leukemicolism 32, 829–843, November 3, 2020 837
Figure 7. GSH Depletion Synergizes with
Conventional Chemotherapy to Reduce
AML Cells In Vivo
(A) Experimental outline combination therapy in
chimeric mice generated as depicted in Figure 3A.
Lethally irradiatedWT recipientswere transplanted
with 106 iMLL-AF9;CD45.2+ BM cells and 106 WT
CD45.1+ BM cells. After two weeks, leukemia was
induced by doxycycline in the food. Upon AML
development, mice were treated with AraC-doxo-
rubicin (Chemo) and BSO or vehicle for 10 days
before flow cytometry analysis.
(B–F) BM leukemic (MLL-AF9+) or WT (B) CD45+
cells, (C) hematopoietic-lineage-negative (lin)
cells, (D) linckit+sca1 (LK) cells, (E) linckit+
sca1+ (LSK) cells, and (F) LSK CD48+ multipotent
progenitors (MPP).
(G) GSH measured by mBCI staining in lin-ckitlow
(LKlo) AML cells from mice treated with combined
BSO therapy (red) or with standard induction
chemotherapy only (black). Each dot represents a
mouse. (B–G) Data are mean ± SEM. *p < 0.05;
**p < 0.01; unpaired two-tailed t test.
(H) Disease-free AML mice treated with combined
BSO therapy (red) or with standard induction
chemotherapy only (black; n = 6).
(I) Disease-free mice after lethal irradiation and
transplantation of BM cells from mice in (H) (n =
4–6). Recipient mice were fed with doxycycline-
containing pellets. (H and I) Logrank test.
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WT counterparts) in mice sacrificed at the same time point (see
STAR Methods); similar trends were observed for Lin- and LK
leukemic cells (Figures 7B–7F). Increased leukemic cell elimina-
tion was associated with 5-fold decreased GSH content in LKlo
putative chemoresistant leukemic cells (Figure 7G). The syner-
gistic effect of BSO and standard chemotherapy significantly
extended mouse survival (Figure 7H). Transplantations of BM
cells from these mice into lethally irradiated recipients showed
a marked reduction of LSC activity after combination therapy
(Figure 7I). Collectively, these findings indicate that neighboring
BMSC can provide AML cells with increased GSH-Gpx activity
to evade chemotherapy and that this chemoprotection mecha-
nism can be therapeutically targeted to improve outcomes.
DISCUSSION
Although it is currently accepted that the BM microenvironment
contributes to AML development and chemoresistance, the un-
derlying cellular and molecular mediators remain largely un-
known. Notably, we and others have found that bulk BM stromal838 Cell Metabolism 32, 829–843, November 3, 2020cells are reduced in AML, raising the
question of which remaining niche cell
populations promote leukemogenesis
and chemoresistance (Baryawno et al.,
2019; Méndez-Ferrer et al., 2020). Our
current study has evaluated the role of
nestin+ BMSCs in AML development and
response to standard chemotherapy.
The results suggest that nestin+ BMSCsprovide LSCs with increased bioenergetics and GSH-related
ROS detoxifying tools, contributing to AML development and
chemoresistance.
Several in vitro studies have suggested functional alterations
of BMSCs in AML, such as reduced proliferation (Corradi et al.,
2018; Desbourdes et al., 2017; Yehudai-Resheff et al., 2019),
increased apoptosis (Desbourdes et al., 2017), impaired differ-
entiation and hematopoietic supporting activity in culture (Doron
et al., 2019; Geyh et al., 2016), inflammatory prolife (Diaz de la
Guardia et al., 2017; Forte et al., 2017; Jacamo et al., 2017;
Kim et al., 2015; Kuett et al., 2015; Reikvam et al., 2015; Ruvolo
et al., 2018; von der Heide et al., 2017), increased support of AML
cells (Ben-Batalla et al., 2013; Brenner et al., 2017; Kornblau
et al., 2018; Wu et al., 2018), and AML protection from chemo-
therapy through increased Notch (Takam Kamga et al., 2016)
or Wnt (Lane et al., 2011) signaling and apoptosis inhibition
(Carter et al., 2016, 2019). However, whether these or other
BMSC alterations play a critical role in AML in vivo has remained
unclear.
Unlike the bulk of BM stromal cells, nestin+ BMSCs were not
diminished in AML patients or in iMLL-AF9 AML mouse model.
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virally expressed MLL-AF9 mouse model (Hanoun et al., 2014)
and contrast with findings in myeloproliferative neoplasms (Ar-
ranz et al., 2014; Drexler et al., 2019), suggesting that the
same niche cells exhibit different alterations and roles in various
myeloid malignancies. Therefore, any strategy targeting the
microenvironment should probably take into account the type
and/or stage of malignancy.
Enforced ~50% reduction of nestin+ cells (Nes-creERT2;iDTA)
caused a similar decrease of HSCs in non-leukemic mice. In
contrast, in vivo nestin+ cell depletion in primary AMLmice signif-
icantly decreased leukemia burden and extended mouse sur-
vival. Moreover, nestin+ cell depletion in chimeric mice carrying
AML cells and WT cells did not affect normal hematopoietic pro-
genitors but selectively decreased leukemia burden. These re-
sults suggest that the HSC niche function of nestin+ cells is
altered in AML to support leukemic cells.
Different studies have shown that AML cells rely on OXPHOS
for chemotherapy resistance (Baccelli et al., 2019; Farge et al.,
2017; Jacque et al., 2015; Lagadinou et al., 2013; Molina et al.,
2018; Pollyea et al., 2018). Among different substrates, AML cells
can use fatty acids as biofuel (Farge et al., 2017). Reduced prolyl
hydroxylase 3, which inhibits fatty acid oxidation (German et al.,
2016), and increased fatty acid-binding protein 4 (Shafat et al.,
2017) allow AML cells utilize fatty acids as substrates for OX-
PHOS. In fact, pharmacological inhibition of fatty acid oxidation
can sensitize human AML cells to apoptosis induction (Samudio
et al., 2010). The metabolic crosstalk between BMSCs and AML
cells was investigated here using a novel coculture system,
where human/murine BMSCs grown as non-adherent mesen-
spheres protected AML cells from chemotherapy-derived
ROS-induced cell death, more efficiently than plastic-adherent
BMSCs. In coculture with mesenspheres, AML cells exhibited
increased OXPHOS, TCA cycle, and ATP production, confirming
that BMSCs increase the bioenergetic capacity of AML cells.
Mitochondrial transfer from mesenspheres to leukemic blasts
increased upon chemotherapy, in agreement with previous
studies using plastic-adherent cells (Marlein et al., 2017; Mo-
schoi et al., 2016). Despite the high ROS levels in AML cells (Li
et al., 2011) and the uptake of ROS-generating mitochondria
from BMSCs, ROS decreased (instead of increasing) in AraC-
treated leukemic blasts cocultured with mesenspheres. The
reason appears to be an augmented antioxidant capacity
conferred by BMSCs.
A comprehensive comparison of transcriptomic changes in
nestin+ BMSCs in AML with those genes differentially expressed
in leukemic LKlo cells of mice with/without nestin+ cell confirmed
OXPHOS and mitochondrial-related pathways in this metabolic
reprogramming and suggested candidate antioxidant mecha-
nisms explaining BMSC protection from excessive ROS. This
was particularly evident after AraC exposure, when proteomic
analysis revealed a significant increase of GSH-related antioxi-
dant proteins in coculture. In fact, GSH increased in AraC-
treated AML cells cocultured with mesenspheres and was
maximal in those leukemic blasts that had uptaken mitochondria
from BMSCs. Interestingly, a TCA cycle metabolite that was
increased in AML cells cocultured with BMSCs—fumarate (Fig-
ure 3K)—has been shown to bind to and activate Gpx1 to oxidize
GSH and protect cells from ROS-induced cell death (Jin et al.,2015). Therefore, BMSC-dependent increase in TCA cycle inter-
mediates (Figure 3K), Gpx1 mRNA expression (Figure 5C) and
GSH recycling (Figures 5 and 6) appear to converge upon
increased Gpx-mediated AML protection from chemotherapy
(Figure 6D). This possibility is supported by clinical data suggest-
ing that mRNA expression of GSH-related antioxidant genes
(including GSS, GPX4, or GSTA1) correlated with poor overall
survival in human AML (Cancer Genome Atlas Research et al.,
2013) (Figures S4B–S4E). Furthermore, Gpx1 inhibition with
MSA abrogated the chemoprotective effect of BMSCs in vitro,
whereas g-GCS inhibition with BSO reduced GSH in vivo and
synergized with standard chemotherapy. Combining BSO with
standard chemotherapy allowed to eliminate chemoresistant
leukemic cells, extend mouse disease-free survival, and signifi-
cantly reduce LSCs measured after transplantations in vivo.
Consistent with our studies, depletion of cysteine has been
recently shown to compromise LSC survival by inhibiting elec-
tron transport complex II (Jones et al., 2019). Along this line, tar-
geting GSH metabolism has been suggested as a promising
avenue to eradicate human AML (Gregory et al., 2019; Pei
et al., 2013). As a novel aspect, our study suggests that BMSCs
play a key role in GSH-dependent AML resistance. Adding up to
our results, these studies suggest that cysteine-GSH might
represent a key vulnerability axis in AML. Notably, the GSH sys-
tem has been shown to critically regulate cancer cell survival in
other malignancies. In chronic (Zhang et al., 2012) or acute
(Boutter et al., 2014) lymphoblastic leukemia, BMSCs (but not
cancer cells) effectively import cystine and convert it to cysteine,
which is then secreted by BMSCs and is uptaken by cancer cells
to generate GSH (Zhang et al., 2012). In summary, our results
add further support to the relevance of GSH-mediated detoxifi-
cation for AML chemoresistance and uncover a critical contribu-
tion from BMSCs to AML metabolic adaptation and survival
in vivo.
Limitations of Study
Although this study demonstrates a key role for NESTIN+ BMSC-
dependent GSH and GPX in antioxidant protection of leukemic
cells against chemotherapy, it does not exclude the possibility
that other antioxidant pathways and cell types contribute to
buffer excessive ROS in AML. Similarly, while the data clearly
involve NESTIN+ cells in antioxidant protection, in vivo BSO
treatment might deplete GSH in various cell types contributing
to the final outcome—a synergistic effect to reduce LSCs
when combined with standard chemotherapy mimicking clinical
AML induction therapy.
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Antibodies
CD3ε (145-2C11) TONBO Biosciences Cat#65-0031-U100; RRID: AB_2810847
Ly-6G (RB6-(C5) BioLegend Cat#127623; RRID: AB_10645331
sca-1 (E13-161.7) BioLegend Cat#108128; RRID: AB_2563064
Lineage Cocktail antibody BD Biosciences Cat#559971; RRID: AB_10053179
c-kit (2B8) eBioscience Cat#11-1171-81; RRID: AB_465185
CD150 (TC15-12F12.2) BioLegend Cat#115927; RRID: AB_11204248
Brilliant Violet 510 Streptavidin BioLegend Cat#405233; RRID: AB_2810848
CD45.1 (A20) BD Biosciences Cat#560578; RRID: AB_1727488
CD45.2 (104) TONBO Biosciences Cat#20-0454; RRID: AB_2621576
Alexa Fluor 488 Sreptavidin-conjugated
antibody
Invitrogen Cat#S32354; RRID: AB_2315383
Mouse Anti-Human CD34
Clone 581 (RUO)
BD Biosciences Cat# 555824, RRID: AB_398614
B220 (RA3-6B2) BD Biosciences Cat#553088; RRID: AB_394618
CD11b (M1/70) BioLegend Cat#101208; RRID: AB_312791
Biotin Rat Anti-Mouse CD31 Clone
MEC 13.3
BD Biosciences Cat#553371; RRID: AB_394817
Biotin Rat Anti-Mouse TER-119/Erythroid
Cells
Clone TER-119 (RUO)
BD Biosciences Cat#553672; RRID: AB_394985
Biological Samples
Human acute myeloid leukemia specimens Cambridge University Hospitals,
Cambridge, UK
REC 07-MRE05-44
Human acute myeloid leukemia specimens University Hospital Sant’Orsola-Malpighi,
Bologna, Italy
94/2016/O/Tess
Chemicals, Peptides, and Recombinant Proteins
Fetal Bovine Serum, charcoal stripped GIBCO Cat#12676029
Cytarabine Cayman Chemical Cat#CAY16069
Collagenase Type I (0.25%) Stem Cell Technologies Cat#07902
Doxorubicin Sigma Cat#D1515
Lympholyte-M Cell Separation Media Cedarlane Cat#CL5031
DMEM, high glucose, GlutaMAX
Supplement, pyruvate
Thermo Fisher Scientific Cat#31966021
RPMI Medium 1640 (1X) no phenol red Thermo Fisher Scientific Cat#11835-063
Murine IL-6 PeproTech Cat#216-16-50
Murine SCF PeproTech Cat#216-16-50
Murine IL3 PeproTech Cat#213-13-100
human PDGF-AA PeproTech Cat#100-13A-100
Human Oncostatin M (227 a.a.) PeproTech Cat#300-10T
Human IL-6 PeproTech Cat#200-06-50
Human FGF-basic (154 a.a.) PeproTech Cat#100-18B
Poly(2-hydroxyethyl methacrylate) Sigma-Aldrich Cat#P3932
Human EGF PeproTech Cat#AF-100-15
Human IGF-I PeproTech Cat#100-11
B-27 Supplement (50X), serum free-10 mL N/A N/A
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N-2 Supplement (100X)-5 mL N/A N/A
Trypsin (0.25%), phenol red Gibco Cat#15050065
DOXYCYCLINE HYCLATE, =98% (HPLC) Sigma-Aldrich Cat#D9891-25G
Penicillin-Streptomycin Thermo Fisher Scientific Cat#15140122
Corning Cell-Tak Cell and Tissue
Adhesive
Fisher Scientific Ltd Cat#CB40240
Dihydrorhodamine 123 Invitrogen Cat#D23806
BODIPY 581/591 C11 (Lipid Peroxidation
Sensor)
Invitrogen Cat#D3861
Monochlorobimane (mBCI) Invitrogen Cat#M1381MP
MitoTracker Red CMXRos Invitrogen Cat#M7512
MitoTracker Green FM Invitrogen Cat#M7514
DAPI Sigma-Aldrich Cat#9542
Mercaptosuccinic acid Sigma-Aldrich Cat#M6182
DMSO Sigma-Aldrich Cat#D5879
buthionine sulfoximine (BSO) N/A Cat#NSC 326231
DTAB Sigma-Aldrich Cat# D8638
0.5M Trizma base Sigma-Aldrich Cat#T1503
Critical Commercial Assays
XF Cell Mito Stress Test Agilent Technologies Cat#103015-100
Seahorse XF Glycolytic Rate Assay Agilent Technologies Cat#103344-100






PowerUp SYBR Green Master Mix Applied Biosystems Cat#A25742
EasySep Human CD271 Positive
Selection Kit
StemCell technologies Cat#17849
ABC amplification kit Vector Labs Cat#AK-5000
Dynabeads mRNA DIRECT Kit Thermo Fisher Scientific Cat#61012
NADP/NADPH Glo Assay Promega Cat#G9081
Clit iT protein enrichment kit Thermo Fisher Scientific (Life Technologies) Cat#C10416
Arcturus Picopure RNA isolation kit Applied Biosystems Cat#KIT0204
Deposited Data
TCGA dataset cBioPortal (Cerami et al., 2012) (Cancer Genome Atlas Research
et al., 2013)
Proteomics data derived from this study This study Peptide Atlas (http://www.peptideatlas.org/
repository/)Accession code: PASS01476
RNAseq data from nestin+ BMSCs obtained
from leukemic iMLL-AF9 and normal mice
This study Gene Expression Omnibus (GEO),
GSE140135
RNAseq data from leukemic BM lin-ckitlo
cells obtained from mice with/without
nestin+ cell depletion
This study Gene Expression Omnibus (GEO),
GSE140207
Experimental Models: Cell Lines
bEnd.3 [BEND3] ATCC Cat#CRL-2299
Experimental Models: Organisms/Strains
congenic CD45.1 C57BL/6 mice Charles River Laboratories N/A
congenic CD45.2 C57BL/6 mice Charles River Laboratories N/A
rtTA;MLL-AF9 mice Stavropoulou et al., 2016
Nes-creERT2 mice Gift from G. Fishell Balordi and Fishell, 2007
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Nes-GFP mice Gift from G. Enikolopov Mignone et al., 2004




















































Kaluza Analysis Software Beckman Coulter GalliosTM Kaluza, RRID: SCR_016700
GraphPad Prism v.8 GraphPad Software GraphPad Prism, RRID: SCR_002798
Seahorse Wave v.2.2.0 Agilent Seahorse Wave, RRID: SCR_014526
FlowJo BD Biosciences FlowJo, RRID: SCR_008520
Thermo Xcalibur Thermo Fisher Scientific Thermo Xcalibur, RRID: SCR_014593
TopHat v2.1.0 Johns Hopkins University, University of
Washington and University of Maryland
TopHat, RRID: SCR_013035
R Project for Statistical Computing R Foundation R Project for Statistical Computing,
RRID:SCR_001905
Proteome Discoverer v.2.1.0.81 Thermo Fisher Scientific Proteome Discoverer, RRID: SCR_014477
ll
OPEN ACCESS Article




Further information and requests for resources and reagents should be addressed to the Lead Contact, Simon Mendez-Ferrer
(sm2116@cam.ac.uk).
Materials Availability
New unique materials were not generated in the course of this study.
Data and Code Availability
All proteomics data derived from this study are deposited in Peptide Atlas (http://www.peptideatlas.org/repository/) and are acces-
sible through the accession number PASS01476. The RNAseq data from nestin+ BMSCs obtained from leukemic iMLL-AF9 and
normal mice has been deposited in GEO under the accession number GSE140135. The RNAseq data from leukemic BM lin-ckitlo
cells obtained from mice with/without nestin+ cell depletion has been deposited in GEO under the accession number
GSE140207. The human AML mRNA expression analysis and associated overall survival Kaplan-Meier estimate are accessible in
the TCGA dataset (Cancer Genome Atlas Research et al., 2013) through the cBioPortal (Cerami et al., 2012). All the other data sup-
porting the findings of this study are available within the article and its supplementary information files and from the lead contact
author upon reasonable request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient Samples
Human AML mononuclear cells were obtained from BM or peripheral blood of patients. Informed consent was obtained in accor-
dance with the Declaration of Helsinki, and the study was conducted under local ethical approval (REC 07-MRE05-44 and 94/
2016/O/Tess). Archival BM biopsies of patients, who consented to the use of their left-over tissue also for research purposes,
from the Institute of Medical Genetics and Pathology at the University Hospital of Basel were utilized for purposes of the study ac-
cording to the regulations of the safety laws of the canton Basel and the Swiss Federal Act on Research involving Human Beings;
handling with probes was approved by the ethics committee of Northwestern Switzerland (EKNZ 2014-252). Samples were derived
from 45 females and 49 males with a mean age of 60±19 years. Sample size was calculated using a = 0.05 and power 85%. No as-
sociation was found between gender or age and NESTIN+ niches.
Mouse Models
8-12 week-old male or female (age and sex-matched) mice were used for experiments. Since no correlation was found between sex
and NESTIN+ niches, both male and female mice were used in this study. Doxycycline-inducible rtTA;MLL-AF9 mice, CD45.2 and
CD45.1 C57BL/6J mice (Jackson Laboratories) were used in this study. Mice were housed in specific pathogen free facilities in indi-
vidually ventilated cages under 12h light/darkness cycles and controlled temperature (19-23)C and humidity (55±10%) with free ac-
cess to standard rodent chow (SafeDiet R105-25). Mice were housed in IVC cages, all diet was irradiated and cages/bedding/envi-
ronmental enrichment was autoclaved. Full cage changes were performed in changing stations and any procedures are carried out in
a CLII cabinet. The Health Monitoring Surveillance Program consisted of the microbiology analysis of mouse sentinels and contact
animals following the FELASA recommendations. Every quarterly period, sentinels and contact animals of the rack were bled for
serology and tested for the agents recommended by FELASA (http://www.felasa.eu/recommendations/recommendation/
recommendations-for-health-monitoring-of-rodent-and-rabbit-colonies/). Once a year, microbiology status of the contact animals
is analyzed by PCR technique using feces and fur/oral swabs; and all sentinels (at the end of the 9-12 months) are euthanized for
bacteriology, parasitology and macro-micro histopathological study (if required) by the CNIC’s microbiology and histology labora-
tories. At Cambridge University, FELASA PLUS screening was performed annually and Klebsiella spp was analyzed as an additional
agent. All screenings revealed no significant findings at either Establishment. All animal procedures conformed to the United
Kingdom Home Office regulations (PPL 70/8406 and P0242B783) and EU Directive 2010/63EU and Recommendation 2007/526/
EC regarding the protection of animals used for experimental and other scientific purposes, enforced in Spanish law under Real De-
creto 1201/2005, and were approved by the local ethics committees and the Animal Protection Area of Cambridge (UK) and the Co-
munidad Autónoma de Madrid (PROEX 154/14).
Generation and full characterization of rtTA;MLL-AF9mice have been described elsewhere (Stavropoulou et al., 2016). Briefly, this
transgenic doxycycline-inducible strain expresses rtTA in the ROSA26 locus and the MLL-AF9 fusion of human origin under the con-
trol of the tetracycline-response element. Upon induction, both the primary rtTA;MLL-AF9 (iMLL-AF9) mice and WT recipients of
iMLL-AF9 BM cells develop a similar type of AML (M4/5) which recapitulates the human disease. In order to follow the development
of normal and leukemic hematopoiesis simultaneously in the same animals, we competitively transplanted lethally irradiated recip-
ients (12 Gy whole body irradiation, split dose 6.0 + 6.0 Gy, 3 h apart) with non-induced, iMLL-AF9 BM (106 cells) and WT BM (106
cells). The CD45.1/2 epitope combination was commonly as CD45.2 for iMLL-AF9 and CD45.1 for WT but it was reversed in some
experiments, with no appreciable differences. Then after 2 weeks under antibiotics, mice were kept with doxycycline (1% in 5%
sucrose water or pellet food 400 mg/kg) to induce transgene expression. Disease progression was monitored every week in tailCell Metabolism 32, 829–843.e1–e9, November 3, 2020 e4
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were over 15 x 103/ul associated with increased percentages in themonocyte and granulocyte cell populations. Mice were sacrificed
at the appropriate endpoints. BM, spleen and blood were analyzed by cell counts, histology and flow cytometry, and cells were used
for functional studies as required.
Different manipulations of the BM microenvironment were achieved through the use of diverse recipient strains. In order to selec-
tively deplete Nes+ cells, Nes-creERT2mice (Balordi and Fishell, 2007) were crossedwith amouse line harboring aCre-inducible diph-
theria toxin gene (iDTA) (Brockschnieder et al., 2006), yielding Nes-creERT2;R26lacZbpAfloxDTA mice (abbreviated as Nes-creER-
T2;iDTA). CreERT2 recombinase was activated by tamoxifen treatment (Sigma) (140mg/kg of tamoxifen, 14mg/ml solution in corn
oil, 3 times/week i.p. on alternate days, typically starting one week after the initiation of doxycycline induction). For combined
Nes+ cell depletion and chemotherapy administration, Nes-creERT2;iDTA and control mice were simultaneously treated with tamox-
ifen (140mg/kg, i.p., 3 doses on alternate days) and AraC (5 daily doses of 100mg/kg, i.p.), starting 2 weeks after MLL-AF9 induction.
For acute response to AraC, AraC was injected 24 hours after a single tamoxifen injection and mice sacrificed for analysis 24 hours
later. For analysis of targeting the GSH antioxidant pathway in vivo, at the disease onset, mice were randomised into two treatment
groups, one given chemotherapy (5+3 regimen with 100mg/kg/d AraC and 3mg/kg/d doxorubicin for 3 days followed by 100mg/kg/
d AraC for 2 days, i.p.) once daily (group Chemo only) and the other chemotherapy in combination with 400mg/kg BSO (i.p., group
Chemo+BSO). After 5 days, daily BSO injections continued for 5 more days, whereas the control group received vehicle injections.
Mice were sacrificed after 11 days for immunophenotypic analysis or at the appropriate endpoints. BM, spleen and blood were
analyzed by cell counts and flow cytometry.
METHOD DETAILS
Immunohistochemistry of Human Samples
For NESTIN/CD34 immunohistochemistry of humanBMsamples, 12 control BMbiopsies (2 from healthy donors, 2 frompatients with
reactive peripheral leukocytosis, and 8 performed for lymphoma staging, but unaffected by lymphoma) and 37 AML (5MLL-AF9+ and
56 with different cytogenetics) were stained for NESTIN applying the monoclonal antibody 10C2 from AbD Serotec (OBT1610) at a
dilution of 1:50 using an automated immunostainer (Benchmark, Ventana/Roche). Antigen retrieval was achieved by cell conditioning
(CC1 fromVentana/Roche) treatment for 60min. Incubation for 60min, signal amplification and visualization (amplifier and chromogen
ultraview universal diaminobenzidine from Ventana/Roche) followed. For NESTIN and CD34 double immunostainings, the anti-CD34
monoclonal antibody QBEnd/10 (Ventana/Roche 790-2927) was used after NESTIN detection and visualized using an alternative
chromogenic detection kit (basic aminoethylcarbazole from Ventana/Roche).
Cell Isolation and Culture
Mesenspheres were cultured from mouse primary BM cells in the following way. Clean mouse bones were crushed in a mortar with
2 ml of a solution containing Collagenase Type I (0.25%) (Stem Cell Technologies). The suspension was incubated for 45 minutes at
37 C in agitation. After addition of PBS+ 2% FBS and passage through a 40 mm cell strainer, erythrocytes were lysed by incubation
on ice with RBC Lysis Buffer. After this, erythroid, endothelial and hematopoietic cells were removed by magnetic depletion after in-
cubation with biotin-conjugated primary antibodies against CD45, Ter119 and CD31 (BD Biosciences, 1:100) and subsequent incu-
bation with streptavidin-conjugatedmagnetic beads (BDBiosciences). For sphere formation, the cells immunomagnetically depleted
of hematopoietic (CD45+), erythroid (Ter119+) and endothelial (CD31+) cells were plated at low density (<500,000 cells/cm2) in ul-
tralow-adherence 35 mm dishes (StemCell Technologies) after treatment with Poly-Hema (Sigma). The growth medium for spheres
contained 0.1 mM b-mercaptoethanol; 1% nonessential amino acids (Sigma); 1% N2 and 2% B27 supplements (Invitrogen); recom-
binant human fibroblast growth factor (FGF)-basic, recombinant human epidermal growth factor (EGF), recombinant human platelet-
derived growth factor (PDGF-AA), recombinant human oncostatin M (227 aa OSM, 20 ng/ml) and recombinant human IGF-1 (40 ng/
ml; Peprotech) in Dulbecco’s modified Eagle’s medium (DMEM)/F12 (1:1) / human endothelial (1:2) serum-free medium (Invitrogen).
Mesensphere medium was supplemented with 15% CEE prepared as described previously (Pajtler et al., 2010) with minor modifi-
cations. Briefly, fertilized chicken eggs were incubated for 11 days at 38C in a humidified incubator. Embryos were washed with
DMEM (Invitrogen), macerated by passage through a 50ml syringe and diluted 1:1 in the samemedium. Hyaluronidase (2 mg, Sigma)
was added to each 50ml tube and incubated 1h at 4Cwith agitation. Following 6 h ultracentrifugation (3x104 g) at 4Cwas decanted
and filtered with 0.45 mm and 0.22 mm sterile filters (Millipore). Aliquots were stored at -80C until use. The cultures were incubated at
37C with 5% CO2, 20% O2 in a water-jacketed incubator and left untouched for 1 week. Afterwards, half-medium changes were
performed twice a week. For passage, spheres were enzymatically dissociated with 100ml Trypsin (EDTA-free) for 10 min at 37C,
applying mechanical dispersion every 10 min. The cells were washed with PBS once and replated with mesensphere medium in ul-
tralow-adherence 35mm dishes (StemCell Technologies).
Human mesenspheres were isolated after magnetic CD271 cell selection using EasySep Human CD271 Positive Selection Kit
(StemCell Technologies) from patients undergoing diagnostic BM aspiration and were grown as previously described (Isern et al.,
2013) and similarly to mouse mesensphere culture described above.
Human AML CD34+ cells were isolated by magnetic cell selection using CD34 MicroBead Kit UltraPure (Miltenyi) after Bone
Marrow (BM) or Peripheral Blood (PB) Mononuclear Cells (MNCs) density gradient centrifugation by Ficoll-Paque.e5 Cell Metabolism 32, 829–843.e1–e9, November 3, 2020
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trogen) without phenol red and supplemented with 10% charcoal-stripped FBS (Gibco), recombinant murine IL3, recombinant mu-
rine SCF and recombinant human IL-6 (10 ng/ml) (Peprotech), 1% Penicillin-Streptomycin, 1 ug/ml doxycycline at 37C in a water-
jacketed incubator with 5% CO2 and 20% O2. Cells were split every other day and seeded at 500,000 cells/ml.
We set up co-cultures systems with mesenspheres (~200 per ml) and leukemic blasts (250,000 cells/ml) for 24h in RPMI without
phenol red and with charcoal-stripped FBS (Gibco) ± cytarabine (AraC, Cayman Chemical, 1mM) in flat-bottom 96-well low adher-
ence tissue cultures plates (Costar) at 37C in a water-jacketed incubator with 5% CO2 and 20% O2. Cultures were grown for 24h
before flow-cytometry staining (apoptosis, ROS levels, lipid peroxidation).
NADP/NADPH Measurement
NADP/NADPH levels in cell were measured using the NADP/NADPH-Glo Bioluminescent Assay kit (Promega G9082) after sorting
leukemic blasts from the cocultures as CD45+ cells. Briefly, after lysing cells in the recommended base solution with dodecyltrimethyl
ammonium bromide (DTAB), the samples were split into separate wells for acid and base treatments (Trizma±HCl). The treated
samples were recorded for luminescence after incubation with NADP/NADPH-Glo Detection Reagent at room temperature
for 40 min.
Seahorse Metabolic Extracellular Flux Profiling
Leukemic blasts (mono-cultured or co-cultured with mesenspheres) were seeded in 24-well plate as above described. After 24h in-
cubation, cells were seeded (500,000 cells/well) in Seahorse 96-well plates coatedwith CellTak (BDBiosciences, San Jose, CA, USA)
to facilitate attachment.
Cell Mito Stress Test (XF Cell Mito Stress Test Kit, Agilent Technologies) was performed following the standard protocol (Nicholls
et al., 2010). Oxygen consumption rate (OCR) and Extracellular Acidification Rate (ECAR) were detected after injection of oligomycin
(1 mM), Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 0.5 mM), and the combination of rotenone & antimycin (Rot/AA,
0.5 mM). OCR was measured with a XF96 analyzer and the Wave software (version 2.2.0) (Seahorse Bioscience).
Flow Cytometry and Fluorescent-Activated Cell Sorting (FACS)
Briefly, after co-culture experiments, cell suspensionwith both types of cells (leukemic blasts andmesenspheres) was centrifuged for
5 min at 300 x g and resuspended in appropriate volume (~1ml). Then, non-aggregated single cells (most of leukemic blasts) were
filtered out by passing through Test Tube with Cell Strainer Snap Cap (35mm nylon mesh) (Corning Falcon) in order to separate
aggregated mesenspheres from leukemic blasts. After flipping the strainer onto a new tube to release all aggregate and after visually
confirming that the aggregates have been rinsed off the filter, leukemic blasts (passed through the filter cap) were collected and
washed. Finally, mesenspheres were treated with trypsin no-EDTA for 10 minutes at 37 C and then were stained for stromal cell
markers in selected experiments (e.g. CD105), whereas leukemic blasts were stained with specific markers (namely CD45, CD34)
in order to gate/sort positive leukemic blasts (mainly CD45+) from negative stromal fraction for FACS experiments.
Leukemic blasts (monocultured or cocultured with BMSCs) were incubated with the appropriate dilution (2-5 mg/ml) of fluorescent
antibody conjugates and were stained in PBS containing 2% FBS at 4C, washed, and analyzed using a Gallios flow cytometer
(Beckman Coulter, Miami Lakes, FL) and Kaluza software (Beckman Coulter).
For immunophenotyping of hematopoietic cell populations, bones (limbs, sternum and spine) were crushed in a mortar, filtered
through a 40-mm mesh to obtain single cell suspensions, and depleted of red blood cells by lysis in 0.15 M NH4Cl for 10 min at
4C. Blood samples were directly lysed in the same buffer for 10 min at room temperature. Cells (1-2 x 106 cells/sample) were incu-
bated with the appropriate dilution (2-5 mg/ml) of fluorescent antibody conjugates and 4’,6-diamidino-2-phenylindole (DAPI) for dead
cell exclusion, and analyzed on FACS Canto II, LSR Fortessa (BD Biosciences, Franklin Lakes, NJ) or Gallios flow cytometer (Beck-
man Coulter, Miami Lakes, FL). FlowJo and Kaluza softwares were used for data analysis. The following antibody conjugates were
used: CD45.1-PE-Cy7 (A20), CD45.2-APC-Cy7 (104), B220-FITC (RA3-6B2), CD11b-PE (M1/70), CD3ε-PerCP-Cy5.5 (145-2C11),
Sca1-PE (E13-161.7), CD34-FITC (RAM34), CD135/Flt3-APC (A2F10.1), and biotinylated lineage antibodies (CD11b, Gr-1,
Ter119, B220, CD3ε), all from BD Biosciences; c-kit-PE-Cy7 or -APC (2B8), from eBioscience (San Diego, CA). Biotinylated anti-
bodies were detected with APC-Cy7-conjugated streptavidin (BD Biosciences).
Intracellular reactive oxygen species (ROS) were detected by staining cells with dihydrorhodamine 123 (DHR123, Thermo Fisher)
following the manufacturer’s recommendations. To assess lipid peroxidation, cells were incubated at a final concentration of 5 mM
C11-BODIPY581/591 (Life Technologies-Invitrogen, Carlsbad, USA). In addition, the cell-permeant probe monochloromobimane
(mBCI, Molecular Probes) was used for quantifying glutathione levels inside cells.
For the analysis of stromal cell populations, boneswere directly crushed in 0.25%Collagenase Type I (StemCell Technologies) and
incubated at 37C for 45 min in a water bath. The resulting cell suspensions were filtered and lysed as above and incubated with
CD45-PE, CD31-APC and Ter119-PE-Cy7 antibodies for 15-20 min at 4C.
For cell sorting, BM samples were processed similarly, except that a lineage depletion step preceded the final staining. For lineage
depletion, cells were first incubated with biotinylated lineage antibodies as above, followed by addition of streptavidin beads (BD
Bioscience) and magnetic depletion. To discriminate between the leukemic blasts and mesenspheres in coculture, CD45 staining
was used after filtration using cell strainer snap cap (35 mM). Populations of interest were separated in a FACS Aria cell sorter (BD
Bioscience).Cell Metabolism 32, 829–843.e1–e9, November 3, 2020 e6
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quently stained with Annexin V-Pacific Blue and SYTOX AADvanced (Invitrogen, Life Technologies, Paisley, UK), following the man-
ufacturer’s instructions.
The transfer of mitochondria was evaluated using a green-fluorescent mitochondrial dye (Mitotracker Green FM) and a red-fluo-
rescent dye (MitoTracker Red CMXRos) (Thermo FisherWaltham, MA USA). Briefly, leukemic blasts were stained with Mitotracker
Green FM (100 ng) and the mesenspheres were separately stained with Mitotracker Red CMXRos (50 ng) for 20min at 37C and
the unbound dyes were removed by extensively washing. The leukemic blasts and themesenspheres were seeded separately in me-
dium for 24h at 37C. Before coculture, both types of cells were washed twice, collected and counted. The transfer of mitochondria
was evaluated by flow cytometry 24h after coculture.
Liquid Chromatography Coupled to Mass Spectrometry (LC-MS) for Metabolomics Analysis
Leukemic blasts (800,000 cells/ml) were cultured alone or in coculture with mesenspheres (250/ml) in normal media for 24h in the
presence of AraC. All the cells were filtered using Falcon tube with cell strainer snap cap (Corning) to mechanically separate leukemic
blasts frommesenspheres. Cells were washed three times with PBS and the extraction buffer (50%methanol, 30% acetonitrile, 20%
water, all LC-MS grade) was added (1ml/4x106 cells). Cell were incubated in dry ice for 15 min, collected, vigorously shaked for
15 min at 4C and left 1h at -20C. Samples were centrifuged at 13,000 rpm and supernatants were transferred to autosampler vials
and stored at -80 C until further analysis. To avoid bias due to machine drift, samples were randomized and processed blindly.
A Q Exactive mass spectrometer (Thermo Fisher Scientific) coupled to a Dionex U3000 UHPLC (Thermo Fisher Scientific) system
was used to perform the LC-MS analysis. A Sequant ZIC-pHILIC column (150 x 2.1 mm, 5 mm) and guard column (20 x 2.1 mm, 5 mm)
(Merck Millipore) were utilized for the chromatographic separation. The column oven temperature was maintained at 40C. The mo-
bile phase was composed of 20mM ammonium carbonate and 0.1% ammonium hydroxide in water (solvent A), and acetonitrile (sol-
vent B). The flow rate was set at 0.2 ml/min with the following gradient: 80% B for 2 min, linear decrease to 20% of B 15 min. Both
solvents were then brought back to initial conditions and maintained for 8 min. The mass spectrometer was operated in full MS and
polarity switching mode. XCalibur Qual Browser and XCalibur Quan Browser software (Thermo Fisher Scientific) were used to pro-
cess and analyze the spectra. Ion intensities indicate raw (not normalized) values.
RNA Isolation and qPCR
RNA isolation was performed using DynabeadsmRNA Purification Kit (Thermo Fisher Scientific 61012). Reverse transcription was
performed using the High-Capacity cDNAReverse Transcription kit (Applied Biosystems 4368814), following themanufacturer’s rec-
ommendations. qPCR was performed using the PowerUp SYBR Green Master Mix (Applied Biosystems A25742) and ABI PRISM
7900HT Sequence Detection System.
The sequences of the primers used are detailed in the Key Resource Table.
RNAseq
For Nestin+ BMSC RNAseq, Nes-GFP+ cells were sorted from the BM of normal or iMLL-AF9+ mice as follows. Leukemia was as
described above by providing doxycycline. Control mice were provided 5% sucrose in water as vehicle. A non-GFP mouse was
used as a control to set up the gating strategy during sorting.
Bones from leukemic or non-leukemic mice were processed as described above and CD45-CD31-Ter119-DAPI-Nes-GFP+ cells
were sorted and immediately frozen at -80C. mRNA was obtained using the RNeasy Kit (Qiagen). Due to low cell number available,
an amplification step was performed as previously described (Picelli et al., 2014). Briefly, the Smart-seq2 protocol was implemented
with improved reverse transcription, template switching and preamplification to increase both yield and length of cDNA libraries
generated from individual cells. Reads were aligned using TopHat version v2.1.0 (Kim et al., 2013) to genome build GRCm38/mm10.
Table S1 shows the analysis of the RNAseq data from Nestin+ BMSCs obtained from leukemic iMLL-AF9 and normal mice.
RNAseq of MLL-AF9+ lin- ckitlo sca1- (LKlo) cells was performed after sorting these cells from the BM of Nes-creERT2;iDTA (N=8) or
control (N=6)mice. Sorted cells were combined for a total of 3 biological replicates (each consisting of pooled LKlo cells from from 2-3
mice). Total RNA was isolated using the Arcturus Picopure RNA Isolation Kit (Thermo Fisher Scientific). RNA was amplified and pre-
pared for RNA-Seq using the Ovation RNA-Seq System v2 (NuGEN) following the manufacturer’s recommendations.
Table S2 shows the analysis of the RNAseq data from leukemic BM lin- ckitlo cells obtained from mice with/without nestin+ cell
depletion.
The RNA sequencing library was prepared with the TruSeq RNA Sample Preparation v2 Kit (Illumina, San Diego, CA) to construct
index-tagged cDNA. The quality, quantity and the size distribution of the Illumina libraries were determined using the DNA-1000 Kit
(Agilent Bioanalyzer). Libraries were sequenced on the Genome Analyzer IIx (Illumina) following the standard RNA sequencing pro-
tocol with the TruSeq SBS Kit v5. Fastq files containing reads for each library were extracted and demultiplexed using Casava v1.8.2
pipeline.
Sequencing adaptor contaminations were removed from reads using cutadapt software tool (MIT) and the resulting reads were
mapped and quantified on the transcriptome (NCBIM37 Ensembl gene-build 65) using RSEM v1.17 (Li and Dewey, 2011). Only genes
with more than 2 counts per million in at least 2 samples were considered for statistical analysis. Data were then normalized and dif-
ferential expression was assessed using the bioconductor package EdgeR (Robinson et al., 2010).e7 Cell Metabolism 32, 829–843.e1–e9, November 3, 2020
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tion, using an empirical Bayes statistic for differential expression (moderated t-test), as implemented in limma package (R/Bio-
conductor). Genes with adjusted p-value % 0.05 were considered to be differentially expressed between the two conditions. Addi-
tionally, in order to detect coordinated changes in sets of genes representing pathways or functional signatures, we performed gene-
set enrichment analyses (GSEA) against the collection of 3144 curated gene sets available in the Molecular Signatures Database
(http://www.broadinstitute.org/gsea/msigdb/index.jsp), including KEGG, Biocarta and Reactome pathways as well as a collection
of gene expression signatures associated with chemical or genetic perturbations. Significance of gene set enrichment between
the two conditions was assessed with GSEA software as previously described (Subramanian et al., 2005) (http://www.
broadinstitute.org/gsea/index.jsp), using a weighted statistic, ranking by signal to noise ratio and 1000 gene-set permutations.
Gene sets with FDR<0.05 were considered to exhibit the most significantly enrichment.
Quantitative Proteomic Analysis
Sample Preparation
Blasts and BMSCs (spheres) pellets were obtained by filtering the culture using 35mm cell strainer snap cap tubes to isolate the
spheres (which did not pass the filter), following isolation of leukemic blasts as CD45+ DAPI- cells. Different conditions included blasts
cultured alone (n=2), blast cultured alone treatedwith AraC (n=3), blast co-culturedwith spheres (n=3), blast co-culturedwith spheres
treatedwith AraC (n=3), spheres cultured alone (n=2), spheres cultured alone treatedwith AraC (n=2), spheres co-culturedwith blasts
(n=3) and spheres co-culturedwith blasts treatedwith AraC (n=4). Each samplewas generated by pooling cells fromdifferent cultures
due to the scarcity of material for each of them. Pellets were extracted in Lysis buffer (50 mM Tris-HCl pH 7.5; 2% SDS, 10 mM TCEP
(Tris(2-carboxyethyl) phosphine hydrochloride (TCEP)) by homogenizing the cells with vortex, boiling for 5 min, and incubating for
30 min at RT with agitation. Samples were centrifuged at 15,000 rpm for 15 min and protein concentration was determined using
a Direct Detect IR spectrometer (Millipore).
Protein Digestion and Isobaric Labelling
For the quantitative differential analysis by LC-MS/MS using isobaric tags (TMT 10-plex), about 100 mg of total proteins were digested
using the FASP protocol as previously described with minor modifications (Cardona et al., 2015). Briefly, proteins were diluted in 7 M
urea in 0.1M Tris-HCl (pH 8.5) (UA), and loaded onto 10 kDa centrifugal filter devices (NanoSep 10kOmega, Pall Life Sciences). Sam-
ples were washed into filters with UA, and proteins were then alkylated with 50 mM iodoacetamide (IAA) in UA for 30 min in the dark.
Samples were washed three times with UA and three additional times with 50 mM ammonium bicarbonate. Proteins were digested
overnight at 37C with modified trypsin (Promega) in 50 mM ammonium bicarbonate at 30:1 protein:trypsin (w/w) ratio. The resulting
peptides were eluted by centrifugation with 50 mM ammonium bicarbonate, and 0.5M sodium chloride. Trifluoroacetic acid (TFA)
was added to a final concentration of 1% and the peptides were desalted onto C18 Oasis-HLB cartridges and dried-down for further
analysis.
For stable isobaric labelling, the resulting tryptic peptideswere dissolved in 30 ml of 100mMTriethylammonium bicarbonate (TEAB)
buffer, and the peptide concentration was determined by measuring amide bonds with the Direct Detect system (Millipore). Equal
amounts of each peptide sample were labelled using the 10-plex TMT Reagents (Thermo Fisher) according to manufacturer’s pro-
tocol. Peptides were labelled with TMT reagents previously reconstituted with 70 ml of acetonitrile, and after incubation at room tem-
perature for 1h, reaction was stopped with 0.5% TFA, incubated for 15 min, and peptides were combined. Samples were concen-
trated in a Speed Vac, desalted onto C18 Oasis-HLB cartridges and dried-down for further analysis. For increasing proteome
coverage, TMT-labelled samples were fractionated by high-pH reverse phase chromatography (High pH Reversed-Phase Peptide
Fractionation Kit, Pierce) and concentrated as before.
Protein Identification
Labelled peptides were analyzed by LC-MS/MS using a C-18 reversed phase nano-column (75 mm I.D. x 50 cm, 2 mm particle size,
AcclaimPepMapRSLC, 100C18; Thermo Fisher Scientific) in a continuous acetonitrile gradient consisting of 0-30%B in 360min, 50-
90% B in 3 min (A= 0.1% formic acid; B=90% acetonitrile, 0.1% formic acid). A flow rate of 200 nL/min was used to elute peptides
from the nano-column to an emitter nanospray needle for real time ionization and peptide fragmentation on an Orbitrap Fusion mass
spectrometer (Thermo Fisher). An enhanced FT-resolution spectrum (resolution=70,000) followed by the MS/MS spectra from the
Nth most intense parent ions were analyzed along the chromatographic run. Dynamic exclusion was set at 40s.
For peptide identification, all spectra were analyzed with Proteome Discoverer (version 2.1.0.81, Thermo Fisher Scientific) using
SEQUEST-HT (Thermo Fisher Scientific). For database searching at the Uniprot database containing all sequences from mouse
and contaminants (April 27, 2016; 48,644 entries), the parameters were selected as follows: trypsin digestion with 2maximummissed
cleavage sites, precursor and fragment mass tolerances of 2 Da and 0.02 Da, respectively. Carbamidomethyl cysteine (+57.021 Da)
and TMTmodifications (+229.162932Da) at N-terminal and Lys residueswere selected as fixedmodifications, andmethionine oxida-
tion (+15.994915 Da) as dynamic modification.
Functional Protein Analysis
Functional protein analysis of the whole set of quantified proteins was performed using our algorithm, system biology triangle (SBT),
developed specifically for the analysis of coordinated protein responses in high-throughput quantitative proteomics experiments
(Garcı́a-Marqués et al., 2016). This algorithm correlates the performance of a group of proteins inside of a category (biological pro-
cess) in terms of their quantitative behavior (relative abundance); thus, changes can be detected in functional biological processes farCell Metabolism 32, 829–843.e1–e9, November 3, 2020 e8
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abundance of annotated functional categories were visualized by comparing the cumulative frequency (sigmoid) plots of the stan-
dardized variable with that of the normal distribution, as previously described (Isern et al., 2013). Briefly, differentially-enriched path-
ways were compared with the predicted cumulative normality plot of the standardized variable at the protein level for all proteins.
Individual protein changes were also considered for further analysis.
Table S3 shows the analysis of the proteomic data from leukemic blasts and spheres in monoculture or coculture upon AraC
treatment.
CBioPortal and TCGA
The human AML mRNA expression analysis and associated overall survival Kaplan-Meier estimate were obtained from the TCGA
dataset (Cancer Genome Atlas Research et al., 2013) in cBioPortal (Cerami et al., 2012).
QUANTIFICATION AND STATISTICAL ANALYSIS
The number of NESTIN+ perivascular niches (either single cells or clusters of up to 3 cells) was blindly scored in human BM samples.
An average area of 7.2mm2 was evaluated for each case.
For qPCR, the expression level of each gene was determined by using the absolute quantification standard curve method. All
values were normalized with Actin as endogenous housekeeping gene.
For RNAseq, gene expression was quantified using featureCounts version 1.5.0 (Liao et al., 2014) with annotation from Ensembl
Release 86 (Yates et al., 2016). Normalization and differential expression were performed using Deseq2 version 1.14.1 (Love et al.,
2014), using R version 3.3.3. Gene ontology enrichment was performed using the R package goseq (Young et al., 2010) for signifi-
cantly differentially expressed genes (padj > 0.05). KEGGpathway enrichment was performed using the R package SPIA (Tarca et al.,
2009) or DAVID (Huang et al., 2007).
For LC-MS/MS peptide identification was performed using the probability ratio method (Martı́nez-Bartolomé et al., 2008) and false
discovery rate (FDR) was calculated using inverted databases, and the refined method (Navarro and Vazquez, 2009) with an addi-
tional filtering for precursor mass tolerance of 10 ppm (Bonzon-Kulichenko et al., 2015). Identified peptides with an FDR equal or
lower than 1% FDRwere used to quantify the relative abundance of each protein from reporter ion intensities, and statistical analysis
of quantitative data were performed using the WSPP statistical model previously described (Navarro et al., 2014). Briefly, in this
model protein log2-ratios are expressed as standardized variables, i.e., in units of standard deviation according to their estimated
variances (Zq values).
Statistical parametric analyses were used after confirming that values followed a normal distribution. Student’s t test was used for 2
group comparison. One-Way ANOVA and Bonferroni comparisons were used for multigroup comparison. Logrank test was used for
survival analysis. p values less than 0.05 were considered statistically significant. Statistical analyses and graphics were carried out
with GraphPad Prism 8 software and Microsoft Excel.e9 Cell Metabolism 32, 829–843.e1–e9, November 3, 2020
